DNA-testing for BRCA1/2 prior to genetic counselling in patients with breast cancer: Design of an intervention study, DNA-direct

BMC Women's Health

Volumn 12, Issue , 2012, Pages

  Sie, Aisha S ^a   Spruijt, Liesbeth ^a   van Zelst Stams, Wendy A G ^a   Mensenkamp, Arjen R ^a   Ligtenberg, Marjolijn J ^a   Brunner, Han G ^a   Prins, Judith B ^a   Hoogerbrugge, Nicoline ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Brca; Breast cancer; Counseling; DNA; Genetic; Hereditary

Indexed keywords

DNA; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISTRESS SYNDROME; FAMILY SIZE; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; INFORMATION PROCESSING; INTERVENTION STUDY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; QUESTIONNAIRE; SATISFACTION; SELF REPORT; SEMI STRUCTURED INTERVIEW; TELECONSULTATION; TUMOR SUPPRESSOR GENE; BREAST TUMOR; COMPARATIVE STUDY; FOLLOW UP; GENETICS; METHODOLOGY; NETHERLANDS; PSYCHOLOGICAL ASPECT;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENETIC COUNSELING; GENETIC TESTING; HUMANS; INTERVENTION STUDIES; NETHERLANDS; QUESTIONNAIRES; RESEARCH DESIGN;

EID: 84860614042     PISSN: None     EISSN: 14726874     Source Type: Journal    
DOI: 10.1186/1472-6874-12-12     Document Type: Article

References (61)

1. Peters E, McCaul KD, Stefanek M, Nelson W. A heuristics approach to understanding cancer risk perception: contributions from judgment and decision-making research. Ann Behav Med 2006, 31:45-52. 10.1207/s15324796abm3101_8, 16472038.
2. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72:1117-1130. 10.1086/375033, 1180265, 12677558.
3. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007, 25:1329-1333. 10.1200/JCO.2006.09.1066, 2267287, 17416853.
4. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302:643-646. 10.1126/science.1088759, 14576434.
5. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251. 10.1016/S0140-6736(10)60893-8, 20609468.
6. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, OConnor MJ, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134. 10.1056/NEJMoa0900212, 19553641.
7. Schwartz MD, Lerman C, Brogan B, Peshkin BN, Halbert CH, DeMarco T, Lawrence W, Main D, Finch C, Magnant C, et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 2004, 22:1823-1829. 10.1200/JCO.2004.04.086, 15067026.
8. Silva E. Genetic counseling and clinical management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations: perspective of a surgical oncologist. Fam Cancer 2008, 7:91-95. 10.1007/s10689-007-9167-3, 17943460.
9. Trainer AH, Lewis CR, Tucker K, Meiser B, Friedlander M, Ward RL. The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol 2010, 7:708-717. 10.1038/nrclinonc.2010.175, 21060331.
10. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244. 10.1016/S0140-6736(10)60892-6, 20609467.
11. Hermsen BB, Olivier RI, Verheijen RH, van Beurden M, de Hullu JA, Massuger LF, Burger CW, Brekelmans CT, Mourits MJ, de Bock GH, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 2007, 96:1335-1342. 2360170, 17426707.
12. Hogg R, Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 2004, 22:1315-1327. 10.1200/JCO.2004.07.179, 15051780.
13. van der Velde NM, Mourits MJ, Arts HJ, de Vries J, Leegte BK, Dijkhuis G, Oosterwijk JC, de Bock GH. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?. Int J Cancer 2009, 124:919-923. 10.1002/ijc.24038, 19035463.
14. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010, 304:967-975. 10.1001/jama.2010.1237, 2948529, 20810374.
15. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009, 101:80-87. 10.1093/jnci/djn442, 2639318, 19141781.
16. Bylund CL, Fisher CL, Brashers D, Edgerson S, Glogowski EA, Boyar SR, Kemel Y, Spencer S, Kissane D. Sources of uncertainty about daughters' breast cancer risk that emerge during genetic counseling consultations. J Genet Couns 2011, 21:292-304.
17. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004, 351:427-437. 10.1056/NEJMoa031759, 15282350.
18. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004, 292:1317-1325. 10.1001/jama.292.11.1317, 15367553.
19. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 2010, 28:222-231. 10.1200/JCO.2009.22.7991, 2815712, 19996031.
20. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001, 345:159-164. 10.1056/NEJM200107193450301, 11463009.
21. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, Van't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004, 22:1055-1062. 10.1200/JCO.2004.04.188, 14981104.
22. Werner-Lin A. Beating the biological clock: the compressed family life cycle of young women with BRCA gene alterations. Soc Work Health Care 2008, 47:416-437. 10.1080/00981380802173509, 19042494.
23. Henselmans I, Sanderman R, Smink A, Ranchor AV, de VJ. Waiting times in breast disease clinics and psychological well-being: speedy care is better care. Ned Tijdschr Geneeskd 2010, 154:B491.
24. Kievit W, de Bruin JH, Adang EM, Severens JL, Kleibeuker JH, Sijmons RH, Ruers TJ, Nagengast FM, Vasen HF, van Krieken JH, et al. Cost effectiveness of a new strategy to identify HNPCC patients. Gut 2005, 54:97-102. 10.1136/gut.2004.039123, 1774368, 15591512.
25. Overbeek LI, Hermens RP, van Krieken JH, Adang EM, Casparie M, Nagengast FM, Ligtenberg MJ, Hoogerbrugge N. Electronic reminders for pathologists promote recognition of patients at risk for Lynch syndrome: cluster-randomised controlled trial. Virchows Arch 2010, 456:653-659. 10.1007/s00428-010-0907-7, 2880231, 20379742.
26. Landsbergen KM, Prins JB, Brunner HG, Kraaimaat FW, Hoogerbrugge N. Genetic testing for Lynch syndrome in the first year of colorectal cancer: a review of the psychological impact. Fam Cancer 2009, 8:325-337. 10.1007/s10689-009-9239-7, 2771129, 19330464.
27. Landsbergen KM, Prins JB, Brunner HG, Hoogerbrugge N. Genetic testing offered directly after the diagnosis of colorectal cancer: a pilot study on the reactions of patients. Genet Couns 2009, 20:317-325.
28. Landsbergen KM, Prins JB, Brunner HG, Hoogerbrugge N. Shortened time interval between colorectal cancer diagnosis and risk testing for hereditary colorectal cancer is not related to higher psychological distress. Fam Cancer 2011, 10:51-57. 10.1007/s10689-010-9387-9, 3036824, 20853153.
29. Berliner JL, Fay AM. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns 2007, 16:241-260. 10.1007/s10897-007-9090-7, 17508274.
30. Harper PS. What do we mean by genetic testing?. J Med Genet 1997, 34:749-752. 10.1136/jmg.34.9.749, 1051060, 9321762.
31. U.S. Preventive Services Task Force Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005, 143:355-361. U.S. Preventive Services Task Force.
32. van Oostrom I, Tibben A. A Counselling Model for BRCA1/2 Genetic Susceptibility Testing. Hered Cancer Clin Pract 2004, 2:19-23. 10.1186/1897-4287-2-1-19, 2839990, 20233480.
33. Andrews L, Meiser B, Apicella C, Tucker K. Psychological impact of genetic testing for breast cancer susceptibility in women of Ashkenazi Jewish background: a prospective study. Genet Test 2004, 8:240-247. 10.1089/gte.2004.8.240, 15727246.
34. Braithwaite D, Emery J, Walter F, Prevost AT, Sutton S. Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis. Fam Cancer 2006, 5:61-75. 10.1007/s10689-005-2577-1, 16528610.
35. Hamilton JG, Lobel M, Moyer A. Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. Health Psychol 2009, 28:510-518. 2807362, 19594276.
36. Heshka JT, Palleschi C, Howley H, Wilson B, Wells PS. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med 2008, 10:19-32. 10.1097/GIM.0b013e31815f524f, 18197053.
37. Meiser B. Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psychooncology 2005, 14:1060-1074. 10.1002/pon.933, 15937976.
38. Schlich-Bakker KJ, ten Kroode HF, Ausems MG. A literature review of the psychological impact of genetic testing on breast cancer patients. Patient Educ Couns 2006, 62:13-20. 10.1016/j.pec.2005.08.012, 16242293.
39. Halbert CH, Stopfer JE, McDonald J, Weathers B, Collier A, Troxel AB, Domchek S. Long-term reactions to genetic testing for BRCA1 and BRCA2 Mutations: does time heal women's concerns?. J Clin Oncol 2011, 29:4302-4306. 10.1200/JCO.2010.33.1561, 21990416.
40. Pieterse AH, Ausems MG, van Dulmen AM, Beemer FA, Bensing JM. Initial cancer genetic counseling consultation: change in counselees' cognitions and anxiety, and association with addressing their needs and preferences. Am J Med Genet A 2005, 137:27-35.
41. Kessels RP. Patients' memory for medical information. J R Soc Med 2003, 96:219-222. 10.1258/jrsm.96.5.219, 539473, 12724430.
42. Metcalfe KA, Poll A, Llacuachaqui M, Nanda S, Tulman A, Mian N, Sun P, Narod SA. Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2. Clin Genet 2010, 78:411-417. 10.1111/j.1399-0004.2010.01499.x, 20653694.
43. Gilpin CA, Carson N, Hunter AG. A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clin Genet 2000, 58:299-308.
44. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002, 20:1480-1490. 10.1200/JCO.20.6.1480, 11896095.
45. Claus EB, Risch N, Thompson WD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat 1993, 28:115-120. 10.1007/BF00666424, 8173064.
46. van Asperen CJ, Jonker MA, Jacobi CE, van Diemen-Homan JE, Bakker E, Breuning MH, van Houwelingen JC, de Bock GH. Risk estimation for healthy women from breast cancer families: new insights and new strategies. Cancer Epidemiol Biomarkers Prev 2004, 13:87-93. 10.1158/1055-9965.EPI-03-0090, 14744738.
47. Bottomley A, Aaronson NK. International perspective on health-related quality-of-life research in cancer clinical trials: the European Organisation for Research and Treatment of Cancer experience. J Clin Oncol 2007, 25:5082-5086. 10.1200/JCO.2007.11.3183, 17991925.
48. Luo N, Fones CS, Lim SE, Xie F, Thumboo J, Li SC. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-c30): validation of English version in Singapore. Qual Life Res 2005, 14:1181-1186. 10.1007/s11136-004-4782-z, 16041912.
49. Goldberg DP, Gater R, Sartorius N, Ustun TB, Piccinelli M, Gureje O, Rutter C. The validity of two versions of the GHQ in the WHO study of mental illness in general health care. Psychol Med 1997, 27:191-197. 10.1017/S0033291796004242, 9122299.
50. Goldberg DP, Oldehinkel T, Ormel J. Why GHQ threshold varies from one place to another. Psychol Med 1998, 28:915-921. 10.1017/S0033291798006874, 9723146.
51. Krespi Boothby MR, Hill J, Holcombe C, Clark L, Fisher J, Salmon P. The accuracy of HADS and GHQ-12 in detecting psychiatric morbidity in breast cancer patients. Turk Psikiyatri Derg 2010, 21:49-59.
52. Horowitz M, Wilner N, Alvarez W. Impact of event scale: a measure of subjective stress. Psychosom Med 1979, 41:209-218.
53. van der Ploeg E, Mooren TT, Kleber RJ, van der Velden PG, Brom D. Construct validation of the Dutch version of the impact of event scale. Psychol Assess 2004, 16:16-26.
54. Hopwood P, Shenton A, Lalloo F, Evans DG, Howell A. Risk perception and cancer worry: an exploratory study of the impact of genetic risk counselling in women with a family history of breast cancer. J Med Genet 2001, 38:139. 10.1136/jmg.38.2.139, 1734804, 11288719.
55. Lerman C, Trock B, Rimer BK, Jepson C, Brody D, Boyce A. Psychological side effects of breast cancer screening. Health Psychol 1991, 10:259-267.
56. Lerman C, Daly M, Masny A, Balshem A. Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol 1994, 12:843-850.
57. Koedoot N, Molenaar S, Oosterveld P, Bakker P, de Graeff A, Nooy M, Varekamp I, de Haes H. The decisional conflict scale: further validation in two samples of Dutch oncology patients. Patient Educ Couns 2001, 45:187-193. 10.1016/S0738-3991(01)00120-3, 11722854.
58. OConnor AM. Validation of a decisional conflict scale. Med Decis Making 1995, 15:25-30. 10.1177/0272989X9501500105, 7898294.
59. User Manual - Decisional Conflict Scale (16 item statement format). http://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Decisional_Conflict.pdf.
60. Vd BS, Gielissen MF, Prins JB. Validation of an empowerment questionnaire in breast cancer survivors 2010, abstract, 12th World Congress of Psycho-Oncology.
61. van Oostrom I, Meijers-Heijboer H, Lodder LN, Duivenvoorden HJ, van Gool AR, Seynaeve C, van der Meer CA, Klijn JG, van Geel BN, Burger CW, et al. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol 2003, 21:3867-3874. 10.1200/JCO.2003.10.100, 14551306.